Literature DB >> 16260385

The shifting patterns of HIV encephalitis neuropathology.

I P Everall1, L A Hansen, E Masliah.   

Abstract

HIV infected macrophages infiltrate the nervous system early in the progression of HIV infection, leading to a complex set of neuropathological alterations including HIV encephalitis (HIVE), leukoencephalopathy and vacuolar myelopathy that in turn result in neurodegeneration of selective cellular populations and pathways involved in regulating cognitive and motor functioning. Rapid progress in the development of highly active antiretroviral therapy (HAART) has changed the patterns of HIV related neuropathology and neurological manifestations in the past 10 years. The prevalence of opportunistic infections and central nervous system (CNS) neoplasms has decreased, and some groups have proposed that the frequency of chronic forms of HIVE have been rising as the HAART-treated HIV population ages. Accordingly, clinical manifestations have shifted from severe dementia forms to more subtle minor cognitive impairment, leading to the suggestion of a classification of HIV associated neurological conditions into an inactive form, a chronic variety, and a 'transformed' variant. From a neuropathological point of view these variants might correspond to: a) aggressive forms with severe HIVE and white matter injury, b) extensive perivascular lymphocytic infiltration, c) 'burnt-out' forms of HIVE and d) aging-associated amyloid accumulation with Alzheimer's-like neuropathology. Factors contributing to the emergence of these variants of HIVE include the development of viral resistance, immune reconstitution, anti-retroviral drug toxicity and co-morbid factors (e.g., methamphetamine, HCV). More detailed characterization of these proposed variants of HIVE is important in order to better understand the pathogenesis of HIV-associated neurological damage and to design more effective treatments to protect the nervous system.

Entities:  

Mesh:

Year:  2005        PMID: 16260385     DOI: 10.1007/bf03033819

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  122 in total

1.  HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Authors:  Jutta K Neuenburg; Hans R Brodt; Brian G Herndier; Markus Bickel; Peter Bacchetti; Richard W Price; Robert M Grant; Wolfgang Schlote
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

2.  Distribution of brain HIV load in AIDS.

Authors:  C A Wiley; V Soontornniyomkij; L Radhakrishnan; E Masliah; J Mellors; S A Hermann; P Dailey; C L Achim
Journal:  Brain Pathol       Date:  1998-04       Impact factor: 6.508

3.  Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for neuroprotection.

Authors:  I P Everall; G Trillo-Pazos; C Bell; M Mallory; V Sanders; E Masliah
Journal:  J Neuropathol Exp Neurol       Date:  2001-03       Impact factor: 3.685

Review 4.  Cellular neuropathology in HIV encephalitis.

Authors:  E Masliah; C L Achim; N Ge; R De Teresa; C A Wiley
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1994

Review 5.  Understanding the AIDS dementia complex (ADC). The challenge of HIV and its effects on the central nervous system.

Authors:  R W Price
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1994

6.  Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry.

Authors:  O Bagasra; E Lavi; L Bobroski; K Khalili; J P Pestaner; R Tawadros; R J Pomerantz
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

7.  HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells.

Authors:  G Zauli; P Secchiero; L Rodella; D Gibellini; P Mirandola; M Mazzoni; D Milani; D R Dowd; S Capitani; M Vitale
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

8.  Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis.

Authors:  H J James; L R Sharer; Q Zhang; H G Wang; L G Epstein; J C Reed; H A Gelbard
Journal:  Neuropathol Appl Neurobiol       Date:  1999-10       Impact factor: 8.090

Review 9.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

10.  Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome.

Authors:  R T Johnson; J D Glass; J C McArthur; B W Chesebro
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  68 in total

Review 1.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

2.  Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.

Authors:  Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-24       Impact factor: 3.568

3.  Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning.

Authors:  Jordan E Cattie; Katie Doyle; Erica Weber; Igor Grant; Steven Paul Woods
Journal:  J Clin Exp Neuropsychol       Date:  2012-06-25       Impact factor: 2.475

4.  Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients.

Authors:  David F Tate; Jared Conley; Robert H Paul; Kathryn Coop; Song Zhang; Wenjin Zhou; David H Laidlaw; Lynn E Taylor; Timothy Flanigan; Bradford Navia; Ronald Cohen; Karen Tashima
Journal:  Brain Imaging Behav       Date:  2010-01-19       Impact factor: 3.978

5.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

6.  Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis.

Authors:  Alessia Bachis; Sadia A Aden; Rachel L Nosheny; Peter M Andrews; Italo Mocchetti
Journal:  J Neurosci       Date:  2006-06-21       Impact factor: 6.167

Review 7.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

Review 8.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 9.  HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis.

Authors:  Marcus Kaul
Journal:  Front Biosci       Date:  2008-01-01

Review 10.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.